Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019

@article{Peters2019LongActingII,
  title={Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019},
  author={Luisa Peters and Amanda Krogmann and Laura von Hardenberg and K. B{\"o}deker and V. B. N{\"o}hles and C. Correll},
  journal={Current Psychiatry Reports},
  year={2019},
  volume={21}
}
  • Luisa Peters, Amanda Krogmann, +3 authors C. Correll
  • Published 2019
  • Psychology, Medicine
  • Current Psychiatry Reports
  • This study was conducted in order to review randomized controlled trial (RCT) data published January 2016–March 2019 on long-acting injectable antipsychotics (LAIs) for schizophrenia. Thirty-one RCTs (primary studies = 7; post hoc analyses = 24; n = 4738) compared LAIs vs. placebo (studies = 11, n = 1875), LAIs vs. oral antipsychotics (OAPs) (studies = 7, n = 658), and LAI vs. LAI (studies = 13, n = 2205). LAIs included two new formulations, aripiprazole lauroxil nanocrystal dispersion and… CONTINUE READING

    Figures and Topics from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 83 REFERENCES